PMID- 29369494
OWN - NLM
STAT- MEDLINE
DCOM- 20190114
LR  - 20190114
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 20
IP  - 5
DP  - 2018 May
TI  - Comparisons of diabetic retinopathy events associated with glucose-lowering drugs 
      in patients with type 2 diabetes mellitus: A network meta-analysis.
PG  - 1262-1279
LID - 10.1111/dom.13232 [doi]
AB  - AIM: To assess the comparative effects of glucose-lowering drugs (GLDs) on the 
      risk of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus 
      (T2DM). METHODS: We systematically searched Cochrane Central Register of 
      Controlled Trials, PUBMED and EMBASE from inception to January 17, 2017 to 
      identify randomized controlled trials (RCTs) that reported DR events among T2DM 
      patients receiving any GLD. Random-effects pairwise and network meta-analyses 
      were performed to calculate odds ratios (ORs) with 95% confidence intervals 
      (CIs). RESULTS: A total of 37 independent RCTs with 1806 DR events among 100 928 
      patients with T2DM were included. The mean duration of diabetes was 8.7 years and 
      mean baseline HbA1c was 8.2% (SD, 0.5%). Our network meta-analysis found that 
      DPP-4i (OR, 1.20; 95% CI, 0.87-1.65), GLP-1RA (OR, 1.19; 95% CI, 0.94-1.52) and 
      SGLT2 inhibitors (OR, 0.79; 95% CI, 0.49-1.28) were not associated with a higher 
      risk of DR than placebo; however, a significantly increased risk of DR was 
      associated with DPP-4i in the pairwise meta-analysis (OR, 1.27; 95% CI, 
      1.05-1.53). Sulfonylureas, on the other hand, were associated with a 
      significantly increased risk of DR compared to placebo (OR, 1.67; 95% CI, 
      1.01-2.76). CONCLUSIONS: Current evidence indicates that the association between 
      DPP-4i, GLP-1RA or SGLT2 inhibitors and risk of DR remains uncertain in patients 
      with T2DM. Some evidence suggests that sulfonylureas may be associated with 
      increased risk of DR. However, given that DR events were not systematically 
      assessed, these effects should be explored further in large-scale, well-designed 
      studies.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Tang, Huilin
AU  - Tang H
AUID- ORCID: 0000-0002-5814-6657
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, China.
AD  - Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana 
      University, Indianapolis, Indiana.
FAU - Li, Guangyao
AU  - Li G
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Sciences, Peking University, Beijing, China.
FAU - Zhao, Ying
AU  - Zhao Y
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Sciences, Peking University, Beijing, China.
FAU - Wang, Fei
AU  - Wang F
AD  - Department of Pharmacy Practice, University of Connecticut, School of Pharmacy, 
      Storrs, Connecticut.
FAU - Gower, Emily W
AU  - Gower EW
AD  - Department of Epidemiology, Gillings School of Global Public Health, University 
      of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
FAU - Shi, Luwen
AU  - Shi L
AD  - Department of Pharmacy Administration and Clinical Pharmacy, School of 
      Pharmaceutical Sciences, Peking University, Beijing, China.
FAU - Wang, Tiansheng
AU  - Wang T
AUID- ORCID: 0000-0002-0980-8896
AD  - Department of Pharmacy, Peking University Third Hospital, Beijing, China.
AD  - Department of Epidemiology, Gillings School of Global Public Health, University 
      of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20180223
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Sulfonylurea Compounds)
SB  - IM
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism
MH  - Diabetic Retinopathy/*chemically induced/epidemiology/prevention & control
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/therapeutic use
MH  - *Evidence-Based Medicine
MH  - Glucagon-Like Peptide-1 Receptor/agonists/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects/therapeutic use
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - Risk
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects/therapeutic use
MH  - Sulfonylurea Compounds/adverse effects/therapeutic use
OTO - NOTNLM
OT  - antidiabetic drug
OT  - diabetic retinopathy
OT  - network meta-analysis type 2 diabetes
EDAT- 2018/01/26 06:00
MHDA- 2019/01/15 06:00
CRDT- 2018/01/26 06:00
PHST- 2017/11/13 00:00 [received]
PHST- 2018/01/11 00:00 [revised]
PHST- 2018/01/19 00:00 [accepted]
PHST- 2018/01/26 06:00 [pubmed]
PHST- 2019/01/15 06:00 [medline]
PHST- 2018/01/26 06:00 [entrez]
AID - 10.1111/dom.13232 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2018 May;20(5):1262-1279. doi: 10.1111/dom.13232. Epub 2018 
      Feb 23.